The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Aurinia Pharmaceuticals Inc shares valued at $32,316 were sold by MacKay-Dunn R. Hector on May 21 ’24. At $5.74 per share, MacKay-Dunn R. Hector sold 5,630 shares. The insider’s holdings dropped to 18,595 shares worth approximately $0.1 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Leversage Jill sold 5,610 shares, netting a total of over 32,201 in proceeds. Following the sale of shares at $5.74 each, the insider now holds 12,918 shares.
Before that, Billen Daniel had sold 5,252 shares from its account. In a trade valued at $30,146, the Director traded Aurinia Pharmaceuticals Inc shares for $5.74 each. Upon closing the transaction, the insider’s holdings decreased to 5,252 shares, worth approximately $0.16 million.
As published in a research note from Oppenheimer on November 04, 2022, Aurinia Pharmaceuticals Inc [AUPH] has been rated down from an Outperform to a Perform. As of December 10, 2021, Oppenheimer has increased its “Perform” rating to a “an Outperform” for AUPH. Earlier on October 28, 2021, Oppenheimer downgraded its rating. Their new recommendation was “a Perform” for AUPH stock which previously was a “an Outperform”.
Analyzing AUPH Stock Performance
During the last five days, there has been a surge of approximately 2.93%. Over the course of the year, Aurinia Pharmaceuticals Inc shares have dropped approximately -37.49%. Shares of the company reached a 52-week high of $9.43 on 01/10/24 and a 52-week low of $4.71 on 04/18/24. A 50-day SMA is recorded $5.30, while a 200-day SMA reached $6.88. Nevertheless, trading volume fell to 0.59 million shares from 0.88 million shares the previous day.
Support And Resistance Levels for Aurinia Pharmaceuticals Inc (AUPH)
According to the 24-hour chart, there is a support level at 5.51, which, if violated, would cause prices to drop to 5.41. In the upper region, resistance lies at 5.67. The next price resistance is at 5.73. RSI (Relative Strength Index) is 56.10 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.07, which suggests the price will decrease in the coming days. Percent R is at 17.54%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Aurinia Pharmaceuticals Inc (AUPH)?
On January 25, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $35.
